Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00406016 |
This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 5 dose regimens of ATI355 in acute spinal cord injury patients
Condition | Intervention | Phase |
---|---|---|
Acute Spinal Cord Injury |
Drug: ATI355 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Multi-Center,Open-Label,Cohort Study to Assess Feasibility,Acute Safety,Tolerability and Pharmacokinetics of 4 Dose of Continuous Intrath. ATI355 Infusion and 1 of Repeated Intrath. Bolus Inj. in Acute SCI Para- and Tetraplegic Patients |
Estimated Enrollment: | 35 |
Study Start Date: | May 2006 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Drug: ATI355 |
Study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 5 dose regimens of ATI355 in acute spinal cord injury patients
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Contact: Novartis Pharmaceuticals | 41 61 324 1111 |
Canada | |
Novartis Investigative site | Active, not recruiting |
Toronto, Canada | |
Novartis Investigative site | Not yet recruiting |
Vancouver, Canada | |
Contact: Novartis Pharmaceuticals +41 61 324 1111 | |
Novartis Investigative site | Active, not recruiting |
Montreal, Canada | |
Novartis Investigative site | Recruiting |
Calgary, Canada | |
Contact: Novartis Pharmaceuticals +41 61 324 1111 | |
Germany | |
Novartis Investigative site | Recruiting |
Bochum, Germany, 44789 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Recruiting |
Bayreuth, Germany, 09445 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Recruiting |
Karlsbad-Lagensteinbach, Germany, 76307 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Recruiting |
Heidelberg, Germany, 69118 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Recruiting |
Murnau, Germany, 82418 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Active, not recruiting |
Ulm, Germany, 89081 | |
Novartis Investigative site | Active, not recruiting |
Bad Wildungen, Germany, 34537 | |
Novartis Investigative site | Recruiting |
Tuebingen, Germany, 72076 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Novartis Investigative site | Recruiting |
Hamburg, Germany, 21033 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 | |
Spain | |
Novartis Investigative site | Active, not recruiting |
Barcelona, Spain, 08002 | |
Novartis Investigative site | Active, not recruiting |
Badalona, Spain, 08911 | |
Switzerland | |
Novartis Investigative site | Recruiting |
Zurich, Switzerland, 8008 | |
Contact: Novartis Pharmaceuticals 41 61 324 1111 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CATI355A2102 |
Study First Received: | November 30, 2006 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00406016 |
Health Authority: | Germany: Paul-Ehrlich-Institut; Switzerland: Swissmedic; Canada: Biologics and Genetic Therapies Directorate. |
Acute spinal cord injury; |
Spinal Cord Injuries Spinal Cord Diseases Wounds and Injuries |
Disorders of Environmental Origin Central Nervous System Diseases Trauma, Nervous System |
Nervous System Diseases |